MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2005.09.041

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2006

French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).

Bensadoun René-Jean, Bénézery Karen, Dassonville Olivier, Magné Nicolas, Poissonnet Gilles, Ramaïoli Alain, Lemanski Claire, Bourdin Sylvain, Tortochaux Jacques, Peyrade Frédéric, Marcy Pierre-Yves, Chamorey Emmanuel, Vallicioni Jacques, Seng Hang, Alzieu Claude, Géry Bernard, Chauvel Pierre, Schneider Maurice, Santini José, Demard François, Calais Gilles

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Unresectable carcinomas of the oropharynx and hypopharynx still have a poor long-term prognosis. Following a previous phase II study, this phase III multicenter trial was conducted between November 1997 and March 2002.

METHODS

Nontreated, strictly unresectable cases were eligible. Twice-daily radiation: two fractions of 1.2 Gy/day, 5 days per week, with no split (D1-->D46). Total tumor doses: 80.4 Gy/46 day (oropharynx), 75.6 Gy/44 day (hypopharynx). Chemotherapy (arm B): Cisplatin 100 mg/m2 (D1, D22, D43); 5FU, continuous infusion (D1-->D5), 750 mg/m2/day cycle 1; 430 mg/m2/day cycles 2 and 3.

RESULTS

A total of 163 evaluable patients. Grade 3-4 acute mucositis 82.6% arm B/69.5% arm A (NS); Grade 3-4 neutropenia 33.3% arm B/2.4% arm A (p < 0.05). Enteral nutrition through gastrostomy tube was more frequent in arm B before treatment and at 6 months (p < 0.01). At 24 months, overall survival (OS), disease-free survival (DFS), and specific survival (SS) were significantly better in arm B. OS: 37.8% arm B vs. 20.1% arm A (p = 0.038); DFS: 48.2% vs. 25.2% (p = 0.002); SS: 44.5% vs. 30.2% (p = 0.021). No significant difference between the two arms in the amount of side effects at 1 and 2 years.

CONCLUSION

For these unresectable cases, chemoradiation provides better outcome than radiation alone, even with an "aggressive" dose-intensity radiotherapy schedule.

Для цитирования: Bensadoun René-Jean, Bénézery Karen, Dassonville Olivier, Magné Nicolas, Poissonnet Gilles, Ramaïoli Alain, Lemanski Claire, Bourdin Sylvain, Tortochaux Jacques, Peyrade Frédéric, Marcy Pierre-Yves, Chamorey Emmanuel, Vallicioni Jacques, Seng Hang, Alzieu Claude, Géry Bernard, Chauvel Pierre, Schneider Maurice, Santini José, Demard François, Calais Gilles. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).. International journal of radiation oncology, biology, physics. 2006. DOI: 10.1016/j.ijrobp.2005.09.041.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.